Table 3.
Hematologic and organ responses in 44 AL patients.
| BCD (n = 22) | BTD (n = 22) | p Value | |
|---|---|---|---|
| Hematologic response | |||
| Complete response (n, %) | 18 (81.8%) | 19 (86.3%) | 0.649 |
| Very good partial response (n, %) | 3 (13.6%) | 2 (9.1%) | 0.865 |
| Partial response (n, %) | 1 (4.5%) | 1 (4.5%) | 1.00 |
| Stable disease | 0 | 0 | |
| Progressive disease | 0 | 0 | |
| Relapse | 1 | 0 | |
| Time to CR achieved (mon.) | 7.71 | 4.97 | 0.010 |
| Cycles for CR achieved (n) | 3 | 2 | 0.742 |
| Dose of Bortezomib for CR (mg/ m2) | 15.6 (15.6–20.8) | 10.4 (10.4–15.6) | 0.013 |
| Mayo clinical 2012 stage CR | |||
| Stage I (n, %) | 9/10 (90.0%) | 9/9 (100%) | 0.500 |
| Stage II (n, %) | 6/8 (75.0%) | 7/9 (77.8%) | 0.727 |
| Stage III (n, %) | 3/3 (100%) | 2/3 (66.6%) | 1.00 |
| Stage IV (n, %) | 0/1 | 1/1 (100%) | |
| Organ response | |||
| Kidney response (n, %) | 11/22 (50.0%) | 13/22 (59.1%) | 0.446 |
| Progression to dialysis (n, %) | 5/22 (22.7%) | 1/22 (4.5%) | 0.588 |
| Time to kidney response (mon.) | 16 (10–16) | 12 (11–16) | 0.735 |
| Cardiac response (n, %) | 1/10 (10.0%) | 3/13 (23.1%) | 0.588 |
| Cardiac progression (n) | 1 | 0 | |
| Progression to multiple myeloma (n) | 1 | 0 | |
| Death (n) | 1 | 0 |